Condition
Safety
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 27 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
27 shownSafety and Tolerability of IRL757 in Participants With Parkinson's Disease and ApathyNCT07461220 · 2026-02-18
RECRUITINGObservational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin RegimenNCT05731258 · 2022-05-01
RECRUITINGAmino Acid Infusion in Kidney Transplant RecipientsNCT06929637 · 2025-09-15
NOT_YET_RECRUITINGSafety of Elacestrant in ER+/HER2- and ESR1 Mutations MBCNCT06544577 · 2024-07-13
UNKNOWNRadiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRTNCT07037680 · 2024-01-01
COMPLETEDEfficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal InsufficiencyNCT06205758 · 2023-11-16
UNKNOWNStereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid TumorsNCT05915481 · 2023-06-21
UNKNOWNStudy on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart FailureNCT05913271 · 2023-05-30
UNKNOWNHuman Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic FootNCT05999656 · 2023-05-28
UNKNOWNUpfront Resection of Locally Advanced NSCLC Followed by ChemoradiotherapyNCT05620199 · 2023-04-01
UNKNOWNEffect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection FractionNCT05964738 · 2022-12-19
COMPLETEDCombination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) StudyNCT05556291 · 2022-12-01
COMPLETEDEfficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's DiseaseNCT05430867 · 2022-07-01
UNKNOWNA Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate CancerNCT05430737 · 2022-06-30
UNKNOWN"Safety in Dementia": An Online Caregiver InterventionNCT05173922 · 2022-05-22
COMPLETEDPD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung CancerNCT05325684 · 2022-04-01
UNKNOWNStudy to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA PatientsNCT05172817 · 2021-06-02
UNKNOWNMidazolam Efficacy/Safety in Pre-Eclamptic C-Section SedationNCT07021521 · 2021-04-05
COMPLETEDA Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With DiabetesNCT05353686 · 2019-02-25
COMPLETEDA Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese DescentNCT03385369 · 2018-01-05
COMPLETEDA Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.NCT02512575 · 2015-11-18
COMPLETEDA Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate AsthmaNCT02479412 · 2015-06-25
COMPLETEDNeoMET Study in Neoadjuvant Treatment of Breast CancerNCT01929811 · 2013-10-01
TERMINATEDA Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and MozambiqueNCT01697007 · 2012-11-01
COMPLETEDPhase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsNCT01576666 · 2012-07-01
COMPLETEDAssessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy VolunteersNCT01348737 · 2011-06-01
COMPLETEDLong-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney DiseaseNCT01309828 · 2011-03-01
COMPLETEDCommon interventions
PlaceboDRUG3stereotactic body radiotherapyRADIATION20 mg/kg Midazolam (Control Group)DRUG10.01 mg/kg Midazolam GroupDRUG10.02 mg/kg Midazolam GroupDRUG10.03 mg/kg Midazolam GroupDRUG1250 µg AZD7594 once dailyDRUG158 µg AZD7594 once dailyDRUG1800 μg AZD7594 once dailyDRUG1Advixa (Adalimumab)DRUG1AnlotinibDRUG1AZD3839DRUG1AZD3839 PlaceboDRUG1AZD9567 MonohydratDRUG1Azilsartan medoxomil and chlorthalidoneDRUG1BKM120DRUG1CadonilimabDRUG1Combinations of Oral Blood Glucose Lowering DrugsDRUG1cyclophosphomideDRUG1Derma Vax ElectroporationDEVICE1Diuretics maintenanceDRUG1Diuretics withdrawalDRUG1DocetaxelDRUG1ELacestrantDRUG1EpirubicinDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
AstraZeneca
3
Yi Han
2
First Affiliated Hospital Xi'an Jiaotong University
1
Getz Pharma
1
Institute for Developing Science and Health Initiatives, Bangladesh
1
Integrative Research Laboratories AB
1
JIANYANG WANG
1
Maimónides Biomedical Research Institute of Córdoba
1
MedImmune LLC
1
Muhimbili University of Health and Allied Sciences
1
Novartis Pharmaceuticals
1
Peking University Third Hospital
1
Pila Pharma
1
SciClone Pharmaceuticals
1
Second Affiliated Hospital, Zhejiang University, School of Medicine
1
Trial status mix
COMPLETED13
UNKNOWN10
RECRUITING2
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE210
PHASE17
NA6
PHASE32
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.